Melanoma gp100 Antikörper (AA 376-502)
Kurzübersicht für Melanoma gp100 Antikörper (AA 376-502) (ABIN7874466)
Target
Alle Melanoma gp100 (PMEL) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 376-502
-
Verwendungszweck
- Melanoma gp100 Antibody / PMEL17
-
Aufreinigung
- Protein G affinity chromatography
-
Immunogen
- A portion of amino acids 376-502 from the human protein was used as the immunogen for the Melanoma gp100 antibody.
-
Isotyp
- IgG1, kappa
-
-
-
-
Applikationshinweise
- Optimal dilution of the Melanoma gp100 antibody should be determined by the researcher.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Store the Melanoma gp100 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
-
-
- Melanoma gp100 (PMEL) (Premelanosome Protein (PMEL))
-
Andere Bezeichnung
- Melanoma gp100
-
Hintergrund
-
Cytotoxic T lymphocytes (CTL's) recognize melanoma-associated antigens, which belong to three main groups. These groups include tumor-associated testis-specific antigens, melanocyte differentiation antigens and mutated or aberrantly expressed antigens, which are routinely used as markers to identify melanomas based on their binding to specific monoclonal antibodies. gp100, also designated ME20-M, ME20-S and PMEL 17, is classified as a melanocyte differentiation antigen and is expressed at low levels in normal cell lines and tissues, but is upregulated in melanocytes. gp100 is a highly glycosylated protein. It is also the product of proteolytic cleavage, which results in a secreted protein.
The gp100 Molecule is a 100 kDa glycosylated protein that is cleaved into a small (26 kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26 kDa and 34-38 kDa fragments.
-
UniProt
- P40967
Target
-